We found that melanoma induction and combination ICI treatment to non-cancer and cancer-bearing mice led to a significant increase in microglial activation (Fig. 4), as shown by elevated hippocampal dual-immunoreactivity for the CD68-IBA1 and TLR4-IBA1 at two months post-combination ICI treatments. The gene discussed is TLR4; the disease is melanoma.